Status:
COMPLETED
Drug Utilisation of Mysimba/Contrave
Lead Sponsor:
Currax Pharmaceuticals
Conditions:
Obesity
Eligibility:
All Genders
Brief Summary
This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Con...
Eligibility Criteria
Inclusion
- At least one prescription of Mysimba/Contrave in his/her medical records any time during the study period (US) OR at least one dispensing of Mysimba/Contrave in his/her registry any time during the study period (Nordic);
- At least 365 days of computerized records prior to first Mysimba/Contrave prescription or dispensing date; and3Patient is active (i.e., alive and registered/accruing data) at the time of the first Mysimba/Contrave prescription or dispensing date.
Exclusion
- \- All patients meeting inclusion criteria will be included in the study; no exclusion criteria will be applied.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
43324 Patients enrolled
Trial Details
Trial ID
NCT06089824
Start Date
September 1 2014
End Date
October 1 2022
Last Update
October 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Currax Pharmaceuticals
Nashville, Tennessee, United States, 37208